PA
MCS icon

PharVision Advisers’s Marcus Corp MCS Stock Holding History

PharVision Advisers’s Portfolio MCS Stock Details MCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,338
Closed -$191K – 424
2025
Q4 		$191K Buy
+12,338
New +$183K 0.1% 576
2025
Q3 		– Sell
-10,678
Closed -$180K – 740
2025
Q2 		$180K Buy
+10,678
New +$180K 0.26% 216
2025
Q1 		– Sell
-13,838
Closed -$298K – 416
2024
Q4 		$298K Buy
+13,838
New +$274K 0.25% 158

Other funds holding MCS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.19B AUM 34.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's MCS Position: Q1 2026 in Review

PharVision Advisers sold out of Marcus Corp (MCS) in Q1 2026, closing a stake of 12,338 shares — an estimated $191K sold.

PharVision Advisers first reported a position in MCS in Q4 2024 and held it in 3 quarters. The position peaked at $298K in Q4 2024. 134 funds tracked by Wall St. Rank hold MCS as of Q1 2026.

  • PharVision Advisers reported no remaining Marcus Corp position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 12,338 Marcus Corp shares in Q1 2026, an estimated $191K.
  • PharVision Advisers first reported a position in Marcus Corp in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Marcus Corp position peaked at $298K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held Marcus Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.